FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas
The Food and Drug Administration has granted accelerated approval to glofitamab-gxbm for relapsed or refractory…
Browsing: FDA Approvals
FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
The Food and Drug Administration has approved talazoparib with enzalutamide for homologous recombination repair (HRR) gene-mutated…
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
The Food and Drug Administration has granted accelerated approval to epcoritamab-bysp for relapsed or refractory…
FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer
On February 9, 2023, the Food and Drug Administration (FDA) approved dostarlimab-gxly for adult patients with…
FDA expands early breast cancer indication for abemaciclib with endocrine therapy
On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib with endocrine therapy…
FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer
On February 3, 2023, the Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy for patients with…
FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab for adjuvant treatment following…
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant for postmenopausal women…
FDA approves zanubrutinib for chronic lymphocytic leukaemia or small lymphocytic lymphoma
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukaemia…
FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma
On December 22, 2022, the Food and Drug Administration (FDA) granted accelerated approval to mosunetuzumab-axgb…